March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
The boom in blank-cheque companies could offer small UK developers a new route to a US stock market listing.
Merck & Co pays $1.9bn for an intriguing but early approach in autoimmune disease.
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
Entresto can now be used in five million of six million US heart failure patients, but Novartis admits ramp-up in the new population will be slow.
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.